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Abstract
Background—Endotoxin has been shown to induce neutrophilic asthma and wheeze after 
binding toll-like receptor 4 to produce pro-inflammatory cytokines. Animal models have 
demonstrated that vitamin D might inhibit lipopolysaccharide-induced cytokines. However, 
whether endotoxin exposure and serum vitamin D deficiency interact to affect asthma and wheeze 
in humans has never been investigated in an epidemiological study.
Methods—Joint associations of house dust endotoxin and vitamin D with asthma and wheeze 
were examined using logistic regression adjusted for covariates in 5,924 US participants of the 
National Health and Nutrition Examination Survey (NHANES). Interactions were assessed on the 
multiplicative as well as additive scale using the relative excess risk, the attributable portion due to 
additive interaction, and the synergy index.
Results—The median endotoxin concentration was 19.1 EU/mg. Prevalence of vitamin D 
inadequacy (20–30 ng/ml) and deficiency (<20 ng/ml) were respectively 42.9 and 33.4%. The 
combination of high endotoxin and low vitamin D was associated with current asthma (OR: 1.56, 
1.09, 2.23), wheeze in the past 12 months (OR: 1.72, 95% CI: 1.10, 3.71), recurrent wheeze (OR: 
1.97, 95% CI: 1.00, 4.00), asthma diagnosis or recurrent wheeze (OR: 1.88, 95% CI: 1.33, 2.66), 
and current asthma or recurrent wheeze (OR:1.81, 95% CI: 1.23, 2.68) when compared to low 
endotoxin and normal vitamin D. Though, the interactions between the exposures were not 
significant on the multiplicative or additive scale for any of the outcomes.
Conclusions—Combination of high endotoxin exposure and low vitamin D increases the odds 
of asthma and wheeze, but the exposures do not interact or modify each other’s effect in the 
NHANES cohort.
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INTRODUCTION
Endotoxin is a lipopolysaccharide constituent of gram-negative bacteria cell walls and is 
ubiquitous in the environment as part of dust and ambient air (1). Known predictors of 
higher endotoxin in homes include lower family income, younger age occupants, carpeting, 
pets, cockroaches or the presence of a smoker in the household (2–4). Endotoxin has been 
proposed to cause asthma and asthma-like symptoms in both occupational and domestic 
settings because of its ability to induce T-helper (Th)-1 response with production of 
interferon (IFN)-γ and neutrophilic inflammation (3, 5). Paradoxically, early life exposure to 
endotoxin has been suggested to prevent later development of immunoglobulin (Ig) E 
mediated asthma and allergy by promoting Th-1 type immune development and inducing 
immune-modulatory effects (6).
Lately, vitamin D has also been of remarkable interest in asthma research because of 
growing reports of a potential relationship between vitamin D deficiency and asthma 
symptoms (7). Sources of vitamin D include diet and sun exposure to ultraviolet B (UVB) 
light which converts 7-dehydrocholestrol in the skin into pre-vitamin D isomerized into 
vitamin D and later converted into 25-OH Vitamin D (25-OH-D) in the liver (8). This 
vitamin has been shown to have immunoregulatory properties that could prevent asthma by 
modifying the effect of Th1, Th2 and regulatory T cells as well as improve asthma control 
by inhibiting Th17 lymphocytes linked to asthma severity and low steroid responsiveness (9, 
10). Hypovitaminosis D is widespread in both developing countries where prevalences range 
between 30 and 90% and developed nations (11, 12). For example, in Europe, recent data 
suggest that serum vitamin D was below 20 ng/ml in 28.2 to 44.4% of Austrians, 40% or 
more of French, 50% or more of Germans and among 67 to 92% of Northern Europeans 
(Denmark, Finland, Ireland and Poland) (12). In the US, according to 2001–2006 National 
Health and Nutrition Examination Survey (NHANES) data, 33% of the population have 
serum vitamin D levels below 20 ng/mL and 77% have levels below 30 ng/mL (13, 14).
Despite the ubiquity of endotoxin in our environment and the high prevalence of low serum 
vitamin D, no epidemiological study has examined whether these two exposures interact to 
affect asthma and wheeze, though each of them has been found independently associated 
with at least one of these conditions. In a previous report using the NHANES, we found that 
endotoxin was independently associated with wheeze and that the relationship between 
endotoxin and asthma and wheeze was influenced by allergen-specific sensitization status as 
well as some environmental exposures (4). Using the same study population, Keet et al 
observed that lower serum vitamin D levels were positively associated with wheeze, asthma 
as well as IgE and noted that the relationship between vitamin D and wheeze was modified 
by age and atopic status (15). The interaction between vitamin D and endotoxin with regard 
to asthma and wheeze has only been studied in animal models, suggesting a potentially 
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synergistic effect in inducing these outcomes. It is established that extracellular monomeric 
endotoxin lymphocyte antigen 96 (LY96) complexes bind to Toll-like receptor (TLR)-4 
triggering intracellular signal transduction cascades resulting in production of the 
proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6, causing 
airway neutrophilic inflammation (16, 17). Both endotoxin induced cytokines have been 
found to be inhibited by serum vitamin D levels at or above 30 ng/ml exerting an anti-
inflammatory action (18). Moreover, it was demonstrated that vitamin D could upregulate 
mitogen-activated protein (MAP) kinase phosphatase-1 (MPK-1) expression by monocytes/
macrophages and thus impede lipopolysaccharide induced phosphorylation of p38, a critical 
regulator of pro-inflammatory cytokines (19). Therefore, in the present study, we aimed to 
test the hypothesis of a potential interactive effect of house dust endotoxin exposure and 
serum vitamin D on asthma and wheeze outcomes in a large epidemiological study 
representative of the US population.
METHODS
Data source and study design
We used data from the NHANES conducted from 2005 to 2006 by the National Center for 
Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) and 
augmented by the National Institute for Environmental Health Sciences (NIEHS) to include 
endotoxin exposure assessment. The NHANES is an ongoing cross-sectional survey of the 
US non-institutionalized civilian population selected using a complex multistage sampling 
design to derive a representative sample of the US population. A total of 6,185 NHANES 
participants had data on house dust endotoxin and serum vitamin D. After exclusion of 261 
participants with missing poverty income ratio data, the final sample included 5,924 
subjects. NHANES protocols were approved by the institutional review boards of the NCHS 
and CDC and informed consent was obtained from all participants. Details on study design 
and procedures can be found in the NHANES website (http://www.cdc.gov/nchs/
nhanes.htm).
Endotoxin measurement
Combined bed and bedroom floor dust samples were collected at each participant’s home 
using a Sanitaire™ Model 3683 vacuum cleaner and a Mitest™ Dust Collector (Indoor 
Biotechnologies, Inc., Charlottesville, VA). One-square yard surfaces on beds and the 
adjacent floors were each vacuumed for two minutes. These composite dust samples were 
analyzed for endotoxin at our University of Iowa laboratory using a kinetic chromogenic 
Limulus amebocyte lysate assay with expansive quality assurance measures as previously 
described (4). Sieved dust was extracted with sterile pyrogen-free water plus 0.05% 
Tween-20™. Control standard endotoxin (E. coli 055:B5) was used to develop 12-point 
standard curves and samples were assayed at four dilutions increasing four-fold from 1:400 
to 1:25,600. Endotoxin concentrations were reported in endotoxin units per sieved dust 
weight (EU/mg of dust). The lower limit of detection was 0.000488 EU/mg.
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Serum vitamin D
25-hydroxy vitamin D (25-OH-D) was measured using the DiaSorin assay, a two-step 
procedure. It consisted of extracting 25-OH-D and other hydroxylated metabolites from 
serum with acetonitrile and assaying the treated sample with an equilibrium RIA procedure 
based on an antibody specific to 25-OH-D. The sample, antibody, and tracer were incubated 
for 90 min at 20–25 °C. Separation was accomplished after a 20-mi nute incubation at 20–
25 °C with another antibody-precipitating complex. A NSB buffer was subsequently added 
after and before centrifugation to help decrease non-specific binding. More detailed 
information about this procedure is available at http://www.cdc.gov/nchs/data/nhanes/
nhanes_05_06/vid_d.pdf.
The Institute of Medicine defines vitamin D deficiency as serum 25-OH-D levels < 20 ng/ml 
(20). In addition, the Endocrine Society Practice Guideline defines vitamin D as inadequate 
at serum 25-OH-D levels between 20 and 30 ng/ml (8). Consequently, we categorized serum 
vitamin D as normal (≥ 30 ng/ml), inadequate (20–30 ng/ml), or deficient (< 20 ng/ml) and 
defined low serum vitamin D as inadequate or deficient (< 30 ng/ml).
Asthma and wheeze
The prevalence of asthma and wheeze were assessed by responses to the following 
questions: (1) “Has a doctor or other health professional ever told you that you/Sample 
Person [SP] had/have/has asthma?” (Asthma diagnosis), (2) “Do you/Does SP still have 
asthma?” (Current asthma), (3) “In the past 12 months, have you/has SP had any wheezing 
or whistling in chest?” (Wheeze in past 12 months), (4) “In the past 12 months, how many 
attacks of wheezing or whistling have you/has SP had?” Past asthma was defined as the 
presence of asthma diagnosis and the absence of current asthma.
Covariates and sensitization
Data on age, gender, race/ethnicity, family income, presence of a smoker in the household, 
number of people in the household, number of years lived in the house, pet avoidance 
because of allergies, as well as presence of mildew, cockroaches, and pets in the homes were 
collected using questionnaires. Poverty income ratio (PIR) was estimated using guidelines 
and adjustment for family size, year and state. Physical activity was evaluated by questions 
related to daily activities, leisure time activities, and sedentary activities (and metabolic-
equivalent task (MET) scores were calculated. Participants’ weight and height were 
measured in a mobile examination center using standardized techniques and equipment. 
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared.
Sensitization status was defined as specific IgE against any of 15 aeroallergens ≥ 0.35 kU/L 
(Alternaria alternata, Aspergillus fumigatus, Bermuda grass, birch, cat dander, cockroach, 
dog dander, dust mites [Der p 1 and Der f 1], mouse urine proteins, oak, ragweed, rat urine 
proteins, Russian thistle, or rye grass). Total and specific IgE levels were measured using the 
Pharmacia Diagnostics ImmunoCAP 1000 System (Kalamazoo, Michigan).
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Statistical analysis
P-values for differences in proportions or means by exposure status were calculated using 
chi-square test for categorical variables and using Student t-test for continuous variables. 
House dust endotoxin was dichotomized into being exposed to levels below or above the 
median, while serum vitamin D was categorized into levels defined earlier (normal, low 
[inadequate or deficient]). Multivariate logistic regression modeling was used to assess the 
association of exposure to dust endotoxin and serum vitamin D combinations with asthma 
and wheeze outcomes. Models were adjusted for age, PIR, MET (used as continuous 
variables), gender, race/ethnicity, number of people in the household, presence of a smoker 
in the household, BMI, number of years lived in the house, presence of mildew, 
cockroaches, and pets in the home, pets avoidance because of allergies, as well as 
sensitization to aeroallergens (used as categorical variables).
Multiplicative interactions were tested by including a product term of endotoxin and vitamin 
D deficiency in the different models. Additive interaction was assessed by calculating the 
relative excess risk due to additive interaction (RERI), the attributable portion (AP) due to 
interaction, and the synergy index (SI) using the methods described by Andersson et al (21). 
Statistical significance was assessed using the 95% confidence intervals (CI), with the AP 
and RERI significantly different from 0 and the SI significantly different from 1 indicating 
the presence of an additive interaction. Age, gender, race/ethnicity, sensitization to allergens, 
and BMI were tested for effect modification by including a product term in the logistic 
regression models. All analyses were performed in STATA (Version 13, STATA Corporation, 
College Station, TX, USA). NHANES sampling weights and STATA survey commands, 
taking into account the multistage and complex survey design, were used in all statistical 
procedures so that estimates were nationally representative. Because of sampling weights, 
traditional procedures for goodness of fit could not be performed; instead STATA, syntax 
svylogitgof, an F-adjusted mean residual test, was used (22). P-values < 0.05 were 
considered statistically significant.
RESULTS
In our study, the median concentration of endotoxin was 19.1 EU/mg of house dust. Only 
23.7% of participants had a normal serum vitamin D, 42.9% had inadequate serum vitamin 
D level, and 33.4% had serum vitamin D deficiency. Our sample consisted of 5,924 people 
with a median age of 37 years (IQR: 20–53, range: 1–85) among whom 51.1% were females 
and 69.3% were non-Hispanic Whites (Table 1). More than half of the participants (54.9%) 
were overweight or obese, 20.2% lived with a smoker in their household, and 41.4% were 
sensitized to allergens. The prevalence of asthma outcomes was 14.7% for asthma diagnosis, 
5.7% for past asthma and 8.8% for current asthma. The prevalence of wheeze outcomes was 
16.5% for any wheeze in the past 12 months and 11.8% for ≥2 wheeze episodes. The 
prevalence of combined outcomes was 20.9% for asthma diagnosis and recurrent wheeze 
(recurrent wheeze being defined as ≥2 wheeze episodes) and 16.0% for current asthma and 
recurrent wheeze.
Participants exposed to lower dust endotoxin levels and with normal serum vitamin D 
represented 13.0% of the study population. They had a median age of 36 years (IQR: 22–
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54); they were more likely to be non-Hispanic White, to have a normal BMI, and to have a 
higher PIR than other participants. Participants with lower exposure to dust endotoxin and 
low serum vitamin D accounted for 43.0% of the study population. They were older (median 
age of 41 years [IQR: 25–54], more likely to be non-Hispanic Blacks, overweight or obese, 
and to be sensitized to aeroallergens compared to other participants. Higher endotoxin 
exposure and normal serum vitamin D was prevalent in only 10.7% of participants. These 
subjects were younger (median age of 24 years [IQR: 8–46]), and more likely to have pets in 
their homes than other participants. Those with higher endotoxin exposure and low serum 
vitamin D were 33.7% and had a median age of 35 years (IQR: 16–52). They were more 
likely to be Hispanic, to have a lower PIR, to have cockroaches in their homes, and to have 
asthma and/or wheeze than the other participants (Table 1).
In reference to low endotoxin exposure and normal serum vitamin D, the combination of 
high endotoxin exposure and low serum vitamin D was associated with nearly all asthma 
and wheeze outcomes: asthma diagnosis (OR: 1.53, 95% CI: 1.20, 1.94), past asthma (OR: 
1.47, 95% CI: 1.00, 2.17), current asthma (OR: 1.56, 1.09, 2.23), any wheeze in the past 12 
months (OR: 1.72, 95% CI: 1.10, 3.71), recurrent wheeze (OR: 1.97, 95% CI: 1.00, 4.00), 
asthma diagnosis or recurrent wheeze (OR: 1.88, 95% CI: 1.33, 2.66), and current asthma or 
recurrent wheeze (OR:1.81, 95% CI: 1.23, 2.68). However, neither the multiplicative nor the 
additive interactions between high endotoxin exposure and low vitamin D were significant 
for any of the asthma or wheeze outcomes (Table 2).
DISCUSSION
The present study used a large sample representative of the US population to examine the 
interaction between house dust endotoxin and serum vitamin D and its relation with asthma 
and wheeze. Our results suggest that the combination of high endotoxin exposure and low 
serum vitamin D is associated with higher odds of asthma and wheeze outcomes. 
Participants with endotoxin exposure above the median and inadequate or deficient serum 
vitamin D were nearly twice as likely to experience two or more wheezing episodes as those 
with low endotoxin and normal vitamin D. However, there was no statistically significant 
interaction between the exposures with regard to their associations with the outcomes
To the best of our knowledge, this is the first report to examine the association of the 
interaction between endotoxin exposure and vitamin D with asthma and wheeze. Endotoxin 
has long been recognized to be an independent risk factor for occupational asthma (23). In 
the first study of national scope conducted in the US (NSLAH), house endotoxin was also 
found to be associated with asthma diagnosis and symptoms as well as asthma medication 
use, mainly in adults (3). Using the NHANES, we performed the largest study ever 
conducted on endotoxin and found bed and bedroom floor endotoxin associated with 
asthma, wheeze, exercise-induced wheeze, and prescription medication for wheezing (4). 
However, there is mounting evidence that endotoxin and other microbial exposures could 
protect against allergic asthma when exposure occurs very early in life (6, 24). Still, the 
association of endotoxin with wheeze appears more consistent in the literature (25).
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Reports on the effect of serum vitamin D on the risk of asthma for their part, have been 
inconsistent. Several cross-sectional as well as prospective and population studies have 
concluded that low vitamin D serum levels increased the risk of asthma and wheeze, 
consistent with our findings of an independent relationship (15, 26–30). Similar associations 
were found for low maternal serum or cord blood vitamin D with later development of 
asthma and wheeze in the offspring (31–34). Still, a number of reports have also failed to 
report an association between vitamin D deficiency and asthma (35–38). A recent meta-
analysis comprising 23 studies suggested that pre- or postnatally measured serum vitamin D 
only plays a role in asthma exacerbation, not asthma development (39). Likewise, clinical 
trials evaluating the efficacy of vitamin D supplementation on asthma and allergy have 
produced conflicting outcomes. In the VIDA (Vitamin D Add-on Therapy Enhances 
Corticosteroid Responsiveness in Asthma) trial, oral vitamin D3 administered 100 000 IU 
once, then 4000 IU per day for 28 weeks did not reduce first treatment failure rates or 
asthma exacerbation in adults with persistent asthma and vitamin D insufficiency in 
comparison to placebo (40). Litonjua et al evaluated the efficacy of prenatal administration 
of vitamin D in preventing asthma and wheeze and also failed to report significant results. 
The study compared 48 women randomized to receive 4400 IU of vitamin D daily with 436 
women who received a placebo whose offspring were followed up to age 3 years (41). In 
another placebo controlled trial including both children and adults, vitamin D 
supplementation (100,000-IU bolus intramuscularly plus 50,000 IU orally weekly for 24 
weeks) significantly improved lung function (forced expiratory volume in 1 sec) in mild to 
moderate persistent asthma (42).
Our analysis failed to find a statistically significant interaction between endotoxin exposure 
and vitamin D deficiency as we had hypothesized based on previous studies, although the 
estimated directionality is not entirely inconsistent with those studies. Studying the effect of 
vitamin D in severe asthma exacerbation and in endotoxin-stimulated cells, Luo et al found 
that vitamin D deficiency enhanced lipopolysaccharide-induced oxidative stress. In their 
investigation, administration of vitamin D3 suppressed lipopolysaccharide-induced reactive 
oxidative species as well as DNA damage and caused a decline in TNF-α and nuclear factor 
(NF)-κB in epithelial cells (43). Similarly, another study noted that normal vitamin D levels 
(30–50 ng/ml) are sufficient to inhibit lipopolysaccharide-induced p38 activation and the 
production of cytokines in monocytes/macrophages. The study additionally identified the 
upregulation of MKP-1 as a new mechanism this p38 activation and cytokine production 
(18). Prior to that, other authors found vitamin D supplementation reduced TLR expression 
and decreased the activation by lipopolysaccharide of MAP kinases. These MAP kinases 
initiate intracellular signal transduction cascades which are critical regulators of pro-
inflammatory cytokine production such as TNF-α and IL-6 (44).
Our study has limitations. Due to the cross-sectional design of the study, temporality 
between endotoxin exposure, low serum vitamin D, and the outcomes cannot be evaluated 
and causality cannot be established. House dust was only sampled once, but dust endotoxin 
and allergens from mattress and bedroom floor have been found to be representative of long 
time exposures (45). Asthma and wheeze outcomes were self-reported and could not be 
verified. There may have been other potential confounding variables, such as familial history 
of atopy and non-residential exposures that were not assessed in the study. Nonetheless, 
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major strengths of our study were the large sample representative of the US population, 
precise measurement of endotoxin, and the analysis adjusted for several exposures, some of 
which could be potential confounders for the associations between endotoxin and asthma or 
wheeze, and socioeconomic factors (such as PIR) to minimize residual confounding.
In conclusion, individuals with low vitamin D exposed to high dust endotoxin exposure are 
at higher odds of asthma and wheeze outcomes than those with normal vitamin D and low 
endotoxin exposure. However, low vitamin D and endotoxin were not significantly 
interactive on the multiplicative or additive scale in their relation with asthma and wheeze.
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Highlights
• Endotoxin exposure and vitamin D deficiency are independently associated with 
asthma and wheeze.
• The combination of high endotoxin and low vitamin D is associated with asthma 
and wheeze.
• Our data do not support an interactive effect of endotoxin and vitamin D on 
asthma and wheeze.
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